Latest Period
Q2 2026
Security Snapshot
Tyra Biosciences, Inc. - Common Stock, $0.0001 par value per share (the "Shares") (TYRA) Institutional Ownership
CUSIP: 90240B106
13F Institutional Holders and Ownership History from Q3 2021 to Q2 2026
Institutions Reporting
169
Shares (Excl. Options)
69,345,946
Price
$31.94
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share (the "Shares")
- Symbol
- TYRA on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 69,345,946
- Total 13F value
- $2,215,485,002
- Portfolio coverage rank
- 0%
- Share change
- +2,897,115
- Value change
- +$58,086,165
- Number of holders
- 169
- Shares outstanding
- 59,226,417
- SEC-reported price per share
- $33.06
- Insider filing price
- $33.06
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- TYRA - Tyra Biosciences, Inc. - Common Stock, $0.0001 par value per share (the "Shares") is tracked under CUSIP 90240B106.
- 169 institutions reported positions in Q2 2026.
- 13 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 163 to 169 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $2,524,644,934 to $2,215,485,002.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 169 institutions filings for Q2 2026.
Security key
90240B106
Latest holder period
Q2 2026
13F holders
169
13D/G owners
13
CIK / CUSIP context first
Open Q2 2026 holders
TYRA full holder history
Tyra Biosciences, Inc. SEC filings
Tyra Biosciences, Inc. company facts
Tyra Biosciences, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 90240B106:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
13
Security
TYRA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 21% | -5.5% | $380,263,825 | +$11,370,397 | 12,266,575 | +3.1% | RA Capital Management, L.P. | 04 Mar 2026 |
| FMR LLC | 14% | +373% | $296,738,016 | +$231,353,566 | 7,747,648 | +354% | FMR LLC | 31 Mar 2026 |
| JANUS HENDERSON GROUP PLC | 7.2% | +36% | $148,931,747 | +$39,592,966 | 3,890,589 | +36% | JANUS HENDERSON GROUP PLC | 31 Mar 2026 |
| Farallon Capital Partners, L.P. | 6.6% | +17% | $137,073,713 | +$22,814,880 | 3,580,818 | +20% | Dapice Joshua J. | 31 Mar 2026 |
| NEXTECH VI ONCOLOGY SCSP | 6% | $115,740,263 | 3,553,585 | Nextech VI Oncology SCSp | 30 Jun 2026 | |||
| BlackRock, Inc. | 5% | $95,060,722 | 2,976,228 | BlackRock, Inc. | 30 Jun 2026 | |||
| Harris Todd | 4.8% | -6% | $111,522,732 | +$3,788,304 | 2,913,342 | +3.5% | Todd Harris | 31 Mar 2026 |
| TCG Crossover GP I, LLC | 5.7% | $29,792,499 | 2,898,103 | TCG Crossover GP I, LLC | 27 Feb 2025 | |||
| Commodore Capital LP | 4.2% | -35% | $94,743,000 | -$34,452,000 | 2,475,000 | -27% | Commodore Capital LP | 31 Mar 2026 |
| Vestal Point Capital, LP | 4.5% | -18% | $33,925,750 | -$6,363,058 | 2,425,000 | -16% | Vestal Point Capital, LP | 30 Sep 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 4% | -48% | $64,574,633 | -$55,131,655 | 2,127,665 | -46% | BVF PARTNERS L P/IL | 31 Dec 2025 |
| Canaan XI L.P. | 1.4% | -68% | $28,725,000 | -$83,511,005 | 750,000 | -74% | Canaan XI L.P. | 31 Mar 2026 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 0% | $195,420 | 6,000 | Farallon Capital Management, L.L.C. | 30 Jun 2026 |
As of 30 Jun 2026, 169 institutional investors reported holding 69,345,946 shares of Tyra Biosciences, Inc. - Common Stock, $0.0001 par value per share (the "Shares") (TYRA). This represents 117% of the company’s total 59,226,417 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
101%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 21% | 12,198,625 | 0% | 3.4% | $389,624,083 |
| FMR LLC | 15% | 8,920,513 | +15% | 0.01% | $284,921,184 |
| Jupiter Topco LLC | 7.3% | 4,352,448 | 0% | 0.06% | $139,161,460 |
| Alta Partners Management Company, L.P. | 6.5% | 3,823,425 | 0% | 96% | $122,120,195 |
| Nextech Invest Ltd. | 6% | 3,553,585 | -12% | 5.4% | $113,501,505 |
| TCG Crossover Management, LLC | 5.5% | 3,248,980 | 0% | 2.5% | $103,772,421 |
| BlackRock, Inc. | 5.1% | 3,031,972 | +37% | 0% | $96,841,186 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.7% | 2,782,567 | +182% | 0.01% | $88,876,000 |
| STATE STREET CORP | 3.6% | 2,140,368 | +76% | 0% | $68,363,354 |
| Commodore Capital LP | 3.2% | 1,875,000 | -24% | 3.6% | $59,887,500 |
| Paradigm Biocapital Advisors LP | 3.1% | 1,828,607 | -11% | 1.1% | $58,405,708 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.5% | 1,508,447 | +34% | 0% | $48,179,797 |
| BVF INC/IL | 2.5% | 1,476,196 | -25% | 1.2% | $47,149,700 |
| 5AM Venture Management, LLC | 1.7% | 1,029,298 | 0% | 11% | $32,875,778 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1.7% | 1,017,000 | +85% | 0.34% | $32,482,980 |
| Hood River Capital Management LLC | 1.7% | 1,016,775 | 0.24% | $32,475,794 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 970,734 | +47% | 0% | $31,010,333 |
| Caligan Partners LP | 1.4% | 806,986 | -37% | 1.2% | $25,775,133 |
| Canaan Partners XI LLC | 1.3% | 750,000 | 0% | 19% | $23,955,000 |
| Siren, L.L.C. | 1.2% | 725,000 | 0.47% | $23,156,500 | |
| Sio Capital Management, LLC | 1.2% | 695,315 | +15% | 3.8% | $22,208,361 |
| STEMPOINT CAPITAL LP | 1.1% | 632,754 | +228% | 3.5% | $20,210,163 |
| MARSHALL WACE, LLP | 0.98% | 583,133 | +195% | 0.02% | $18,625,268 |
| GOLDMAN SACHS GROUP INC | 0.78% | 463,477 | -16% | 0% | $14,803,455 |
| JENNISON ASSOCIATES LLC | 0.76% | 450,964 | -29% | 0.01% | $14,403,791 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
20
Latest
Q2 2026
Rows shown
1-20 of 20
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 69,345,946 | $2,215,485,002 | +$58,086,165 | $31.94 | 169 |
| 2026 Q1 | 65,938,350 | $2,524,644,934 | +$382,078,810 | $38.30 | 163 |
| 2025 Q4 | 56,830,609 | $1,493,991,866 | +$12,760,989 | $26.29 | 133 |
| 2025 Q3 | 55,638,635 | $778,399,313 | -$9,877,671 | $13.99 | 115 |
| 2025 Q2 | 56,588,644 | $541,513,140 | +$28,813,504 | $9.57 | 120 |
| 2025 Q1 | 53,573,458 | $499,522,930 | +$34,676,031 | $9.30 | 116 |
| 2024 Q4 | 48,613,623 | $675,760,666 | -$145,254,713 | $13.90 | 112 |
| 2024 Q3 | 47,054,295 | $1,105,994,170 | +$8,152,750 | $23.51 | 94 |
| 2024 Q2 | 46,814,701 | $748,570,507 | -$1,810,347 | $15.99 | 76 |
| 2024 Q1 | 46,852,011 | $768,372,899 | +$182,484,246 | $16.40 | 75 |
| 2023 Q4 | 35,756,693 | $495,188,385 | -$9,797,725 | $13.85 | 62 |
| 2023 Q3 | 36,462,633 | $502,118,395 | +$3,284,853 | $13.77 | 59 |
| 2023 Q2 | 36,210,809 | $616,671,033 | +$8,028,494 | $17.03 | 59 |
| 2023 Q1 | 35,654,296 | $572,964,060 | +$8,455,742 | $16.07 | 50 |
| 2022 Q4 | 35,239,863 | $267,821,738 | -$5,207,345 | $7.60 | 45 |
| 2022 Q3 | 35,692,923 | $313,754,295 | -$403,922 | $8.79 | 43 |
| 2022 Q2 | 35,744,229 | $255,572,000 | -$3,322,156 | $7.15 | 44 |
| 2022 Q1 | 36,133,976 | $386,624,000 | -$8,627,515 | $10.70 | 46 |
| 2021 Q4 | 35,174,367 | $494,157,000 | +$13,654,547 | $14.07 | 45 |
| 2021 Q3 | 26,080,552 | $456,755,000 | +$456,755,000 | $17.59 | 25 |